Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 2/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | CETP | P11597 | 6/20 | 0.68 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.67 |
| ▸ | ACP1 | P24666 | 2/20 | 0.67 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.64 |
| ▸ | CTSD | P07339 | 1/20 | 0.64 |
| ▸ | PTPRF | P10586 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.64 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237280 | 1.00 | POLB (0.73) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL12181569 | 1.00 | POLB (0.73) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL15163860 | 0.95 | POLB (0.67) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL15163868 | 0.95 | POLB (0.67) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL22335282 | 0.94 | POLB (0.75) | POLBRECQLCETPPTPN2PTPN1 | |
| SCHEMBL3952674 | 0.92 | POLB (0.70) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL22201041 | 0.92 | PTPN1 (0.66) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL13523639 | 0.90 | PTPN1 (0.66) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL7163156 | 0.88 | EGFR (0.67) | POLBRECQLEGFRCETPPTPN2 | |
| SCHEMBL29386542 | 0.88 | EGFR (0.67) | POLBRECQLEGFRCETPPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571354-B1 | Ursolic acid for inhibiting muscle atrophy | UNIV IOWA RES FOUND (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20180118657-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2018-05-03 | — | — | US | disclosed |
| US-20140371188-A1 | COMPOSITIONS AND METHODS FOR INHIBITING MUSCLE ATROPHY AND INDUCING MUSCLE HYPERTROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-12-18 | — | — | US | disclosed |
| US-20130203712-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2011146768-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371188-A1 | COMPOSITIONS AND METHODS FOR INHIBITING MUSCLE ATROPHY AND INDUCING MUSCLE HYPERTROPHY | CDKN1A, MUSK, MSTN | POLB 1232/4885RECQL 3617/4885EGFR 1742/4885 |
| US-20180118657-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | TNNC1, PYGM, GYS1 | POLB 3218/4885RECQL 4199/4885EGFR 4815/4885 |
| US-20130203712-A1 | METHODS FOR INHIBITING MUSCLE ATROPHY | TNNC1, PYGM, GYS1 | POLB 3218/4885RECQL 4199/4885EGFR 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.